ETON

Eton Pharmaceuticals Inc

ETON, USA

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

https://www.etonpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ETON
stock
ETON

Eton Pharmaceuticals (NASDAQ:ETON) Downgraded by Wall Street Zen to Hold Defense World

Read more →
ETON
stock
ETON

FY2025 EPS Estimate for Eton Pharmaceuticals Cut by Analyst Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$30

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

19.42

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-8.33 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.84 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

52.28 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.52

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 64.18% of the total shares of Eton Pharmaceuticals Inc

1.

Opaleye Management Inc

(10.6647%)

since

2025/06/30

2.

EcoR1 Capital, LLC

(7.5717%)

since

2025/06/30

3.

BlackRock Inc

(5.7116%)

since

2025/06/30

4.

Vanguard Group Inc

(4.893%)

since

2025/06/30

5.

Nantahala Capital Management, LLC

(4.385%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.5591%)

since

2025/07/31

7.

iShares Russell 2000 ETF

(2.3317%)

since

2025/08/31

8.

Geode Capital Management, LLC

(2.2107%)

since

2025/06/30

9.

Morgan Stanley - Brokerage Accounts

(1.9001%)

since

2025/06/30

10.

Divisadero Street Capital Management, LP

(1.8559%)

since

2025/06/30

11.

Westside Investment Management, Inc.

(1.763%)

since

2025/06/30

12.

Renaissance Technologies Corp

(1.5136%)

since

2025/06/30

13.

Cannell Capital LLC

(1.4475%)

since

2025/06/30

14.

Thompson, Siegel & Walmsley LLC

(1.4217%)

since

2025/06/30

15.

State Street Corp

(1.2052%)

since

2025/06/30

16.

Soleus Capital Management, L.P.

(1.0627%)

since

2025/06/30

17.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0268%)

since

2025/07/31

18.

Northern Trust Corp

(0.9778%)

since

2025/06/30

19.

Fidelity Small Cap Index

(0.9579%)

since

2025/06/30

20.

JPMorgan Chase & Co

(0.9046%)

since

2025/06/30

21.

iShares Russell 2000 Growth ETF

(0.8304%)

since

2025/08/31

22.

Connor Clark & Lunn Inv Mgmt Ltd

(0.8281%)

since

2025/06/30

23.

Two Sigma Investments LLC

(0.8%)

since

2025/06/30

24.

UBS Group AG

(0.7923%)

since

2025/06/30

25.

Aristides Capital LLC

(0.6249%)

since

2025/06/30

26.

Fidelity Extended Market Index

(0.5127%)

since

2025/07/31

27.

Vanguard Russell 2000 ETF

(0.4562%)

since

2025/07/31

28.

Bridgeway Ultra-Small Company

(0.3955%)

since

2025/06/30

29.

State St Russell Sm Cap® Indx SL Cl I

(0.3375%)

since

2025/08/31

30.

Calamos Timpani Small Cap Growth I

(0.245%)

since

2025/07/31

31.

Schwab Small Cap Index

(0.2408%)

since

2025/07/31

32.

Timpani Small Cap Growth Equity

(0.2382%)

since

2025/06/30

33.

NT R2000 Index Fund - NL

(0.2314%)

since

2025/06/30

34.

iShares Micro-Cap ETF

(0.2169%)

since

2025/08/31

35.

Extended Equity Market Fund K

(0.2007%)

since

2025/06/30

36.

iShares Core S&P Total US Stock Mkt ETF

(0.1872%)

since

2025/08/31

37.

NT R2000 Index Fund - DC - NL - 3

(0.1845%)

since

2025/06/30

38.

Fidelity Total Market Index

(0.177%)

since

2025/07/31

39.

iShares Russell 2000 Small-Cap Idx Instl

(0.1656%)

since

2025/07/31

40.

SPDR® Russell 2000 US Small Cap ETF

(0.1469%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.2

Latest Release

Date

2025-09-30

EPS Actual

0.04

EPS Estimate

0.11

EPS Difference

-0.07

Surprise Percent

-63.6364%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(3.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.